Company Coverage
TA: Trip.com Group (9961 HK) / Innovent Biologics (1801 HK)
Analyst


Analyst
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at the following link: https://research-api.uobkayhian.com/assets/disclaimer/0e6d602f-adeb-45f8-9dea-5d5591daae87, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
Our latest research
2 Oct 2026
TA: CSPC Pharmaceutical Group (1093 HK) / China Resources Power Holdings (0836 HK)

2 Oct 2026
New World Development (17 HK): FY26: Core Profit Turns Positive; 11 SKIES Exit Helps Long-term Cash Flow, But Debt Metrics Warrant Caution
30 Sept 2026
